Samarasinghe Amali, Chan Arlene, Hastrich Diana, Martin Richard, Gan Albert, Abdulaziz Farah, Latham Margaret, Zissiadis Yvonne, Taylor Mandy, Willsher Peter
Medical, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Medical Oncology, Breast Cancer Research Centre-WA, Nedlands, Western Australia, Australia.
Asia Pac J Clin Oncol. 2019 Dec;15(6):337-342. doi: 10.1111/ajco.13240. Epub 2019 Sep 10.
The objective of this study was to evaluate patient compliance with management recommendations given by a breast cancer multidisciplinary team (MDT), assess for reasons for noncompliance, and perform an exploratory assessment on breast cancer outcomes in noncompliant patients.
A retrospective analysis of prospectively collected data was undertaken for patients selected by their primary clinician to be discussed at the MDT of Breast Cancer Research Centre-WA in Perth between 1st March 2011 and the 28th February 2016. The primary objective was the rate of compliance with MDT management recommendations. Secondary objectives included factors associated with noncompliance, rate of clinical trial uptake, and impact of treatment noncompliance on breast cancer events in a subgroup of early breast cancer (EBC) patients.
A total of 2614 MDT management recommendations were made for 925 patients. Overall, 92% were compliant with all recommendations given. Clinical trial recruitment was successful in 84.1%. The reasons given for treatment noncompliance were fear of toxicity, choosing an alternative treatment, and treatment inconvenience. In a subset of 337 EBC patients, there was a significantly higher rate of contralateral breast cancer, distant recurrence, and breast cancer-specific death, P = .0016, in those who were noncompliant. Our study demonstrates a high rate of MDT treatment recommendation compliance and clinical trial recruitment. In a subgroup of EBC patients, noncompliance was associated with significantly worse outcomes. Attention to educating patients to minimize their fear of treatment toxicity and ensuring their understanding of evidence-based treatment may lead to lower rates of noncompliance.
本研究的目的是评估患者对乳腺癌多学科团队(MDT)给出的管理建议的依从性,评估不依从的原因,并对不依从患者的乳腺癌结局进行探索性评估。
对2011年3月1日至2016年2月28日期间由其初级临床医生选择在珀斯乳腺癌研究中心 - 西澳的MDT进行讨论的患者的前瞻性收集数据进行回顾性分析。主要目标是MDT管理建议的依从率。次要目标包括与不依从相关的因素、临床试验参与率,以及治疗不依从对早期乳腺癌(EBC)患者亚组中乳腺癌事件的影响。
共为925名患者提出了2614条MDT管理建议。总体而言,92%的患者依从所有给出的建议。临床试验招募成功率为84.1%。治疗不依从的原因包括对毒性的恐惧、选择替代治疗以及治疗不便。在337名EBC患者的亚组中,不依从患者的对侧乳腺癌、远处复发和乳腺癌特异性死亡发生率显著更高,P = 0.0016。我们的研究表明MDT治疗建议的依从率和临床试验招募率很高。在EBC患者亚组中,不依从与明显更差的结局相关。关注对患者进行教育以尽量减少他们对治疗毒性的恐惧,并确保他们理解基于证据的治疗,可能会降低不依从率。